41 results about "Viral Inactivation" patented technology

The invention provides a method for detecting a virus inactivation effect by an ELISA (Enzyme-Linked Immunosorbent Assay) method, which comprises the following steps: acquiring a to-be-detected inactivated virus sample, extracting an antigen component from the sample, and detecting an antigen structure change characteristic value through a high-throughput mass spectrometry analysis technology to obtain antigen degradation degree data; obtaining a sample subjected to preliminary inactivation, and detecting the antigen content change trend through an enzyme-linked immunosorbent assay to obtain content change curve data; detecting the residual quantity of viral nucleic acid by a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) technology aiming at the immunogenicity retained sample to obtain nucleic acid degradation degree data; acquiring nucleic acid degradation degree data, classifying the relationship between nucleic acid residues and infectivity by adopting a support vector machine algorithm, and judging that the inactivation effect is completely completed if the classification result shows that the infectivity is lost; according to the antigen content change trend, the immunogenicity index and the nucleic acid degradation degree data, a weighted fusion algorithm is adopted to integrate multi-dimensional detection results, and a comprehensive inactivation effect score is obtained.

The invention relates to the technical field of biological medicines, in particular to a soluble skin-adhering microneedle for delivering an inactivated enterovirus vaccine as well as a preparation method and application of the soluble skin-adhering microneedle. Sodium hyaluronate is adopted as a film forming material to wrap an enterovirus 71 type (EV71)-coxsackie virus A16 (CA16) type bivalent inactivated vaccine antigen, and a needle body layer of the soluble microneedle is formed; the substrate layer is prepared from a pullulan material, so that the microneedle patch with a stable overall structure is formed. The technology provided by the invention is completed in a clean environment, and the vaccine patch which is qualified through sterility detection is obtained. The soluble microneedle disclosed by the invention has good antigen stability under the condition of 2-8 DEG C. In animal experiments, the microneedle is attached to the skin surface of a mouse for skin-adhering immunization, a strong immune response reaction can be induced, good immunogenicity is shown, and a novel, safe and effective vaccine delivery way is provided for prevention and control of the infantile hand-foot-and-mouth disease.

The invention discloses an akabane virus inactivated vaccine preparation method, which comprises: carrying out Vero cell passage in a cell bottle, taking well growing cells until the cells grow to 80-90%, adding into a DMEM culture medium containing 10% of fetal calf serum, taking out the cells growing to 80-90% and having a good state, adding akabane virus CH-JL-01-2022 according to a volume ratio of 0.1%, and carrying out culture at a temperature of 80-90 DEG C so as to obtain the akabane virus inactivated vaccine. Culturing for 2-3 days in an incubator with the temperature of 37 DEG C and 5% CO2; the method comprises the following steps: preparing 0.25 M BEI, 0.1 M BPL and a 40% formaldehyde solution as inactivators, setting five concentration gradients according to the volume ratios of 0.01%, 0.05%, 0.1% and 0.5%, and collecting after 6 hours, 12 hours, 24 hours, 36 hours and 48 hours after adding; the screening of the akabane virus inactivation conditions according to the types, concentrations and inactivation time of inactivators finds that 0.5% formaldehyde shows a complete inactivation effect after inactivation for 36 hours. The inactivated virus liquid is mixed with MONTANIDETM ISA 201, an ImjectI aluminum adjuvant and a manganese adjuvant according to the volume ratio of 1: 1, and then immunization is carried out, and the protection effect of the ImjectI aluminum adjuvant is found to be optimal.

The invention provides an application of trichostatin A in promotion of RNA virus proliferation, and belongs to the field of chemical medicines. The invention discloses a novel application of trichostatin A. The trichostatin A can effectively promote the-1 Ribosomal Frameshift process of RNA viruses, can effectively promote replication and proliferation of the RNA viruses, can be used for preparing products for promoting proliferation of the RNA viruses and can be used for producing and preparing RNA virus inactivated vaccines or attenuated vaccines, and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses. And the production cost can be effectively reduced, the production period is shortened, and wide application prospects and economic values are achieved.

The application belongs to the technical field of protein purification, and particularly relates to a recombinant human metapneumovirus pre-fusion F protein purification method, which comprises the following steps: filtering fermentation broth by using a deep filter to obtain fermentation clarified liquid; capturing the recombinant hMPV F protein from the fermentation clarified liquid by using hydroxyapatite to obtain purified liquid 1; inactivating viruses in the purified liquid 1 by using a low-pH method to obtain inactivated liquid; performing anion exchange chromatography on the inactivated liquid to obtain purified liquid 2; performing composite weak anion chromatography on the purified liquid 2 to obtain purified liquid 3; performing UF / DF on the purified liquid 3 to obtain ultrafiltrate; and performing virus-removing nanofiltration and sterile filtration on the ultrafiltrate to obtain a recombinant hMPV F stock solution. The method is simple, reproducible, suitable for large-scale production, and can be effectively used for producing a recombinant human metapneumovirus pre-fusion F protein vaccine.

A viral inactivation composition includes an aqueous solution of citric acid and L-arginine hydrochloride with a pH below 3.5. The citric acid and L-arginine hydrochloride are present in amounts that directly inactivate COVID-19, influenza, and common cold virus in a human upper respiratory system. A method of directly inactivating COVID-19, influenza, and common cold virus in the human upper respiratory system includes administering the viral inactivation composition to a subject. These ingredients are safe, non-toxic, and very effective.

The application discloses a natural recombination novel duck reovirus variant (NDRV-GXNN-2025) strain, which has a preservation number of CCTCC No:V202613 and a preservation date of January 28, 2026. Researches show that the NDRV-GXNN-2025 strain has high pathogenicity to ducklings and goslings, and the mortality rates of 2-day-old ducklings and goslings are 30% and 50% respectively when the attack dose is 104.0 / 0.1ml; meanwhile, the strain has good immunogenicity and is an ideal vaccine candidate strain. Accordingly, the inventors also establish a preparation method of a corresponding inactivated vaccine. The novel duck reovirus inactivated vaccine prepared by the method has good stability and safety, can induce the body to produce high-level neutralizing antibodies after immunizing ducklings and goslings, and can effectively resist the attack of the novel duck reovirus variant, and has a good application prospect.

The present invention provides intravenous pharmaceutical compositions comprising engineered plant virus-based nanoparticles for the treatment or prevention of autoimmune conditions. The nanoparticles display immunodominant peptides that induce immune tolerance in a subject when administered intravenously. The invention further provides methods of manufacturing virus-based nanoparticles, including production in plant expression systems and optional viral inactivation, to render them suitable for therapeutic use in mammals. Also provided are methods of intravenous administration of the pharmaceutical compositions to a subject in need thereof for treating or preventing autoimmune conditions.

To satisfy a need for methods and reagents utilized during sample handling for viral inactivation, thereby rendering samples non-infectious and providing safer sample handling conditions.SOLUTION: Methods of utilizing sample lysis reagent compositions in handling of samples containing viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. The reagent composition comprises a nonionic octylphenol ethoxylate surfactant and water. Kits containing the sample lysis reagent compositions are also disclosed.SELECTED DRAWING: Figure 1

To provide a compact virus infection preventing apparatus capable of effectively preventing virus infection, having high treatment capacity for inactivating viruses and good in operability.SOLUTION: In the virus infection prevention device, the air washing section includes a tubular barrel section having a connection port with the air supply hose at one end and an opening at the other end, a first air supply fan and a first ultraviolet light emitting diode provided in this order inward of the connection port, a second air supply fan and a second ultraviolet light emitting diode provided in this order inward of the opening, and a reflecting mirror between the first ultraviolet light emitting diode and the second ultraviolet light emitting diode. The reflecting mirror has a cylindrical body portion, a first inclined portion provided at one end portion of the cylindrical body portion and substantially matching a light distribution angle of ultraviolet rays emitted from the first ultraviolet ray emitting diode, and a second inclined portion provided at the other end portion of the cylindrical body portion and substantially matching a light distribution angle of ultraviolet rays emitted from the second ultraviolet ray emitting diode.SELECTED DRAWING: Figure 2

The application relates to a tube reactor module for controlling a reaction time of a process fluid in dynamic operation, in particular during viral inactivation in the process fluid, comprising: an inlet for receiving the process fluid; an outlet for discharging the process fluid; a tubular flow path comprising a serpentine pattern for guiding the process fluid from the inlet to the outlet, the tubular flow path comprising a sequence of fluidly connected alternatingly bent curve sections, wherein each curve section is shaped such that a flow direction of the process fluid changes by at least approximately 90°, in particular by between approximately 135° and 225°, and wherein the tubular flow path comprises a first cross-section perpendicular to the flow direction of the process fluid at respective apexes of the curve sections and a second cross-section perpendicular to the flow direction of the process fluid at respective end portions of the curve sections, wherein the first cross-section is different from the second cross-section.

The invention relates to a method for purifying a target substance starting from a fluid to be treated which comprises at least one impurity. The method comprises treatment of a stream of the fluid to be treated using a chromatography step in a first separation unit, collection of a fraction enriched with the target substance in a first tank, and viral inactivation of the fraction enriched with the target substance. The viral inactivation comprises passing the fraction enriched with the target substance through a second separation unit, passing a viral inactivation solution through the second separation unit, mixing, and collecting the mixture in the second tank to obtain a fraction depleted of active virus. The method further comprises treatment of the fraction depleted of active virus using a chromatography step in the second separation unit and collection of a fraction more enriched with the target substance.

To provide a virus inactivator that exhibits a viral inactivation effect for envelope viruses and also exhibits a superior viral inactivation effect for non-envelope viruses.SOLUTION: A virus inactivator comprising a phytic acid and at least one of the following component (A) and component (B). Component (A): at least one alkanediol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, and 1,2-decanediol. Component (B): at least one oily component selected from the group consisting of lavender oil, camphor leaf oil, rosemary oil, peppermint oil, copaiba oil, squalane, and liquid paraffin.SELECTED DRAWING: None

The invention relates to a method for inactivating an enveloped virus in a biopharmaceutical-containing fluid, said method comprising exposing said fluid to a substituted cyclodextrin. The invention also relates to a method for purifying and / or producing a biopharmaceutical comprising exposing a biopharmaceutical-containing fluid to a substituted cyclodextrin.

The content of the invention consists in the concept of an intelligent object / room supply and disinfection system which is harmless to health and the mode of action of which is based on the use of electromagnetic waves of the UV spectral range both for the generation of the bacterial and viral disinfection potential and for the transmission of audio, video and data information. The invention is directed to the operability of the following classes or areas of application and ensures bacterial and viral inactivation of animate stationary and mobile enclosed or semi-enclosed:1. large objects such as cultural, sports and event venues;2. institutional and public objects such as buildings of public life, health care, education and higher education;3. cabins such as the passenger cabins of land, air and sea passenger transportation means;4. objects of animal breeding, animal husbandry and veterinary medicine.The inactivation is based on the continuous-wave interaction of electromagnetic radiation fields within the wavelength range between 190 nm and 230 nm and the programmable and / or auto-adaptive generation capability of continuous and / or discrete radiation spectra with controllable temporal and spatial signal signatures.

The invention discloses a method for separating human immune globulin from plasma, which comprises the following steps: S1, plasma pretreatment: filtering fresh plasma by using a 0.45 mu m filter membrane, adjusting the pH value to 5.0-5.5, adding PEG6000 (Polyethylene Glycol 6000) with the final concentration of 2% to precipitate impure protein, and centrifuging to take supernatant; s2, cation exchange chromatography: loading the supernatant to a Capto S Impact chromatographic column, balancing by using a sodium acetate buffer solution containing 50-100 mM of NaCl, carrying out gradient elution by using 0-500 mM of NaCl, and collecting an IgG main peak; s3, hydrophobic chromatography: adjusting the concentration of ammonium sulfate in the eluent in S2 to 1.0 M, loading to a Phenyl HP column, carrying out reverse gradient elution by using 1.0-0 M ammonium sulfate, and collecting a target peak; s4, virus inactivation: 0.3% of Tween-80 and 0.25% of TNBP are added, and incubation is performed for 6 hours at the temperature of 25 DEG C; and S5, ultrafiltration sterilization: concentrating to 100 mg / mL by using a 30 kDa tangential flow ultrafiltration system, and filtering and sub-packaging at 0.22 mu m. Through the CEX-HIC coupling technique, gradient elution optimization and integrated virus inactivation, efficient, low-cost and safe production of high-purity intravenous injection IgG is achieved, and the method is particularly suitable for large-scale application in the blood product industry.

The invention belongs to the technical field of aquatic immunity and biological preparations, and discloses a mutant IL-7 protein and application of the mutant IL-7 protein as a grass carp reovirus inactivated vaccine adjuvant. The applicant obtains the IL-7 mutant mIL-7 with higher receptor binding capacity on the basis of grass carp IL-7. After the mIL-7 and the GCRV-II type inactivated vaccine are combined to immunize the grass carp, the expression of immune related genes is obviously up-regulated, the IL-10 is obviously reduced, the enzyme activities of CAT, ACP and Gpx in serum are also obviously improved, and the AST is obviously reduced. A challenge experiment result shows that the survival rate of the grass carp combined with the mIL-7 and the inactivated vaccine is increased by about 10%, and the VP56 virus load in the body is reduced. As an immunologic adjuvant, the mutant IL-7 can effectively enhance the specific immune response and disease resistance of the grass carp, can be used as an efficient and safe adjuvant of a grass carp inactivated vaccine, and has good safety and application prospects.

The invention relates to a non-guanidine salt type compatible nucleic acid extraction virus preservation solution as well as a preparation method and application thereof, and the virus preservation solution comprises P (HEMA-BAMPD hydrochloride), a buffer agent, a chelating agent, a saccharide stabilizer and an osmotic pressure regulator. The P (HEMA-BAMPD hydrochloride) is used for replacing guanidine salt and small molecule quaternary ammonium salt, the inactivation rate effect on enveloped RNA / DNA viruses such as SARS-CoV-2 viruses and influenza viruses is good, no irritation is generated, and the method is friendly to operators and the environment; the macromolecular structure realizes multi-point adsorption and has strong organic matter interference resistance, and a small amount of blood, sputum and other components in the sample do not influence the inactivation effect. Moreover, the P (HEMA-BAMPD hydrochloride), the chelating agent and the saccharide stabilizer have a synergistic effect, so that the activities of RNase and DNase can be effectively inhibited.

The invention belongs to the technical field of aquatic immunity and biological preparations, and discloses a CXCL20a protein mutant and application of the CXCL20a protein mutant as a grass carp reovirus inactivated vaccine adjuvant. In order to improve the immunomodulatory activity of CXCL20a, the applicant constructs and obtains a CXCL20a mutant protein. After the mutant and a GCRV-II type inactivated vaccine are combined to immunize grass carp, the expression of immune related genes can be remarkably promoted, the activity of serum acid phosphatase and superoxide dismutase is enhanced, and meanwhile, the level of lactic dehydrogenase is reduced. A challenge experiment proves that the survival rate of the grass carp combined with the inactivated vaccine for immunization is increased by about 8% compared with that of a non-mutant combined group, and the in-vivo virus load is reduced. As an immunologic adjuvant, the CXCL20a mutant M-C20 provided by the invention can effectively enhance early immune response and overall protection effect in vaccine immunity, and has good safety, stability and application prospect.

This sterilization / viral inactivation device comprises a microorganism adhesion part identification unit that identifies a microorganism adhesion part which is a part to which a microorganism adheres in an object space where a person enters and exits, a substance generation unit that generates a specific substance for performing sterilization treatment or inactivation treatment of the microorganism, and a transportation unit that generates an air flow in the object space and transports the specific substance toward the object microorganism, and the sterilization / viral inactivation device performs a sterilization treatment or inactivation treatment in the object space.

The application discloses a striped jack iridovirus inactivated vaccine and a preparation method thereof. The striped jack iridovirus SD strain virus liquid is used to prepare the striped jack iridovirus inactivated vaccine with high safety and good immunoprotective effect. The inactivated vaccine can effectively reduce the mortality of the striped jack after the striped jack is infected with the striped jack iridovirus, fills the blank of the inactivated vaccine for the striped jack iridovirus, and is helpful to the prevention and control of the striped jack iridovirus disease.

The application discloses a preparation method and application of a Seneca Valley Virus disease inactivated vaccine for pigs, and the vaccine is prepared by using the following steps: suspending culture of Seneca Valley Virus, chromatographic purification of an antigen, and preparation of the vaccine by using an optimized water adjuvant. The Seneca Valley Virus inactivated vaccine prepared by the method has good safety, can induce piglets to generate high-level neutralizing antibodies, and effectively protects a pig group from the attack of a Seneca Valley Virus virulent virus for pigs.

The invention discloses an evaluation method and a kit for rapidly testing the inactivation effect of an African swine fever live virus. The method can eliminate misjudgment on the inactivation effect of the ASFV live virus caused by the defect that common PCR (Polymerase Chain Reaction) or qPCR (Quantitative Polymerase Chain Reaction) still can detect the DNA (Deoxyribose Nucleic Acid) of the inactivated ASFV. The invention can provide a rapid and practical evaluation method and kit for testing the ASFV live virus inactivation effect for pigs in China.

The application relates to a tube reactor module for controlling a reaction time of a process fluid in dynamic operation, in particular during viral inactivation in the process fluid, comprising: an inlet for receiving the process fluid; an outlet for discharging the process fluid; a tubular flow path comprising a serpentine pattern for guiding the process fluid from the inlet to the outlet, the tubular flow path comprising a sequence of fluidly connected alternatingly bent curve sections, wherein each curve section is shaped such that a flow direction of the process fluid changes by at least approximately 90°, in particular by between approximately 135° and 225°, and wherein the tubular flow path comprises a first cross-section perpendicular to the flow direction of the process fluid at respective apexes of the curve sections and a second cross-section perpendicular to the flow direction of the process fluid at respective end portions of the curve sections, wherein the first cross-section is different from the second cross-section.

This invention discloses a data-driven modeling and predictive control method for respiratory virus inactivation, relating to the field of biomedical technology. The method includes the following steps: obtaining initial viral characteristic data from a viral surface structure database through molecular dynamics simulation, processing the data to obtain a structural change matrix of the virus under different inactivation conditions; using a support vector machine classifier based on the structural change matrix to extract features of viral characteristics and antibody binding sites, determining a set of potential unexpected interaction sites. This data-driven modeling and predictive control method for respiratory virus inactivation effectively improves the scientific validity and stability of inactivation process parameters, reduces safety risks caused by improper inactivation conditions, shortens the process optimization cycle, reduces experimental costs, and helps maintain good immunogenicity while ensuring the safety of virus inactivation, thereby better meeting the practical application needs in vaccine development and virus prevention and control.

The invention relates to the field of biological medicines, and particularly provides a purification method of an anti-IL-11 monoclonal antibody, which comprises the following steps: affinity chromatography: preliminarily purifying and concentrating a target protein containing the anti-IL-11 monoclonal antibody, and carrying out virus inactivation on a protein product in an acid solution to obtain a protein sample; anion exchange chromatography: carrying out secondary purification on the protein sample, and collecting flow-through liquid; and cation exchange chromatography: carrying out refined purification on the flow-through liquid to obtain a protein solution of the anti-IL-11 monoclonal antibody. A proper purification process is provided for the anti-IL-11 monoclonal antibody, the purification efficiency and the recovery rate of the anti-IL-11 monoclonal antibody are improved, flow-through liquid collected by anion exchange chromatography directly enters cation exchange chromatography without treatment, sample treatment or solution replacement is not needed in the process, the purification time is saved, and the purification efficiency and the recovery rate of the anti-IL-11 monoclonal antibody are improved. Impurities are prevented from being introduced in the purification process, the purity of purified protein is improved, and high practicability is achieved.

The instant invention relates to compositions of, and methods for producing, a virus-inactivated antibody preparation having a reduced level of high molecular weight aggregates, and / or methods for minimizing formation of high molecular weight aggregates in a virus-inactivated antibody preparation, comprising an antibody, or antigen-binding portion thereof, e.g., an anti-CD40 antibody or antigen binding portion thereof.

The invention provides a recombinant rabies virus capable of simultaneously expressing a canine distemper virus H protein and a canine parvovirus VP2 protein between a G gene and an L gene, the recombinant rabies virus has better genetic stability and replication ability, and after the virus is inactivated, mice are immunized, so that the mice can simultaneously generate neutralizing antibodies for resisting RABV, CDV and CPV.

The invention provides a virus inactivating agent hydrolysis system and hydrolysis method, and belongs to the technical field of biologication.The virus inactivating agent hydrolysis system comprises a reaction tank, a feeding assembly, a flushing assembly, a discharging assembly, a stirring assembly and a control system, and the reaction tank comprises an inner container, a heating structure and a heat preservation layer; the feeding assembly is provided with a liquid inlet pipe, and a first electric control valve is arranged on the liquid inlet pipe; the flushing assembly comprises a steam pipe, a flushing pipe and a flushing head, and second electric control valves are arranged on the steam pipe and the flushing pipe; the discharging assembly is arranged at the bottom of the reaction tank, the discharging assembly is provided with a first discharging opening, a second discharging opening, a third discharging opening and a third electric control valve, and the third electric control valve is used for controlling one of the first discharging opening, the second discharging opening and the third discharging opening to be opened; the control system is in communication connection with the heating structure, the first electric control valve, the second electric control valve and the third electric control valve.

The present application relates to a kind of non-guanidine salt type compatible nucleic acid extraction virus preservative and preparation method and application, the virus preservative, including P (HEMA-BAMPD) hydrochloride, buffer, chelating agent, saccharide stabilizer and osmotic pressure regulator.The present application replaces guanidine salt and small molecule quaternary ammonium salt with P (HEMA-BAMPD) hydrochloride, and the inactivation rate effect of SARS-CoV-2 virus, influenza virus and other envelope type RNA / DNA viruses is good, and there is no irritability, and it is friendly to operating personnel and environment;Polymer structure realizes multiple point adsorption, and the ability of resistance to organic interference is strong, and a small amount of blood, sputum and other components in sample do not affect inactivation effect.Moreover, P (HEMA-BAMPD) hydrochloride, chelating agent and saccharide stabilizer synergistic effect can effectively inhibit RNase, DNase activity.